Fulcrum Therapeutics (FULC) Payables (2019 - 2025)
Historic Payables for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $2.9 million.
- Fulcrum Therapeutics' Payables fell 2932.44% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 2932.44%. This contributed to the annual value of $1.2 million for FY2024, which is 5778.02% down from last year.
- According to the latest figures from Q3 2025, Fulcrum Therapeutics' Payables is $2.9 million, which was down 2932.44% from $1.8 million recorded in Q2 2025.
- Fulcrum Therapeutics' Payables' 5-year high stood at $6.0 million during Q1 2022, with a 5-year trough of $1.2 million in Q4 2024.
- Moreover, its 5-year median value for Payables was $3.7 million (2021), whereas its average is $3.6 million.
- As far as peak fluctuations go, Fulcrum Therapeutics' Payables skyrocketed by 3101.17% in 2023, and later crashed by 6092.82% in 2025.
- Quarter analysis of 5 years shows Fulcrum Therapeutics' Payables stood at $4.8 million in 2021, then dropped by 24.02% to $3.6 million in 2022, then fell by 24.22% to $2.8 million in 2023, then plummeted by 57.78% to $1.2 million in 2024, then surged by 145.36% to $2.9 million in 2025.
- Its Payables stands at $2.9 million for Q3 2025, versus $1.8 million for Q2 2025 and $1.5 million for Q1 2025.